May 30 |
FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea
|
May 29 |
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
|
May 23 |
ADHD diagnoses increasing, becoming an 'expanding public health concern': CDC
|
May 21 |
Teva, Alvotech launch biosimilar against AbbVie’s Humira
|
May 21 |
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
|
May 18 |
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
|
May 17 |
Insider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...
|
May 16 |
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
|
May 15 |
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
|
May 14 |
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)
|